Introduction
The characteristic of Parkinson's disease (PD) is damage to dopaminergic neurons in the substantia nigra pars compacta (SNpc) leading to lowered levels of dopamine and, consequently, motor http://dx.doi.org/10.1016/j.neulet.2016.02.011 0304-3940/© 2016 Elsevier Ireland Ltd. All rights reserved. Table 4 Results of generalized regression analysis with a severity score based on progression of PD (i.e., 0 = controls; 1 = PD stage 1; 2 = PD stage 2; and 3 = PD stage 3) as dependent variable and the oxidative stress biomarkers and C-reactive protein as explanatory variables. glutathione in the brain [2] . Signs of O&NS are also observed in the peripheral blood of PD patients, including increased lipid hydroperoxides (LOOH), higher levels of by-products of nitric oxide (NOx) and changes in antioxidants [3] . The activity of catalase (CAT), one of the antioxidant enzymes, is reduced in the brain of PD patients [4] . Sulphydryl groups (-SH), which are part of the antioxidant system were found to be lowered in PD patients [5] . In PD, post mortem studies showed increased activity of encephalic superoxide dismutase (SOD), which converts superoxide to hydrogen peroxide (H 2 O 2 ) in the cytoplasm and mitochondria and is a first line defense against increased ROS production [6] .
Another antioxidant enzyme that has been studied in PD is paroxonase 1 (PON 1). It is bound to high-density lipoprotein and plays a key role in protecting both low-and high-density lipoproteins from oxidation. Lowered PON-1 activity increases risk to neurodegenerative diseases as well as other IO&NS-related pathologies [7] . PON 1 polymorphisms are associated with the development of PD [8] . Moreover, decreased plasma PON 1 was reported in patients with insecticide-induced PD [9] .
In addition to the involvement of O&NS processes in PD, inflammatory mechanisms also contribute to the pathophysiology and staging of disease (chronicity and disease progression). Evidence of inflammatory events in PD include activated microglia and increased levels of inflammatory biomarkers such as tumor necrosis factor (TNF)-␣, interleukin (IL)-1, IL-6 and C-reactive protein (CRP) [10] . Since it is known that CRP can activate microglia, it could be expected that elevated CRP levels in PD take part in the neuro-inflammatory pathophysiology and thus in disease severity or progression [11] .
The aim of this study was to examine systemic IO&NS biomarkers in PD. We expected to find that PD is accompanied by increased IO&NS biomarkers reminiscent of lipid peroxidation (lipid hydroperoxides, malondialdehyde), nitric oxide metabolism (NOx) and inflammation (CRP), lowered levels of most antioxidants (total radical trapping antioxidant parameter, CAT activity, SH-groups and PON 1), but elevated SOD activity.
Subjects and methods

Subjects
The study population consisted of 56 PD patients recruited from the neurology ambulatory at Clinical Hospital, State University of Londrina. PD was diagnosed according to the criteria of the United Kingdom PD Society Brain Bank (UKPD). Patients were included and classified into two groups: early PD stage (corresponding to stage 1 according Hoehn-Yahr scale) with unilateral involvement and late PD stage (corresponding to stages 2 + 3 according HoehnYahr scale) to with bilateral or midline involvement. The control group (n = 56), i.e., apparently healthy individuals, was matched for gender, age and ethnicity to the patients.
Patients with clinical or laboratory evidence of autoimmune, renal, heart, liver and other neurological diseases, including multiple sclerosis, stroke, Alzheimer's disorder, major depression and chronic fatigue syndrome, alcohol dependence and use of antioxidant supplements were excluded from both the PD and control groups. Most PD patients were treated with drugs: levodopa and carbidopa (n = 13), levodopa and benserazide (n = 37), pramipexole (n = 30), amantadine (n = 12), biperiden (n = 7) and/or entacapone (n = 5). Twelve patients were taking antidepressants (amitriptyline or fluoxetine). Written informed consent was obtained from all patients and controls. The study was approved by the Ethics Committee on Research Involving Human Subjects of the State University of Londrina (protocol n • 222/2011).
Methods
Blood was collected after an overnight fast (10 h). Total radicaltrapping antioxidant parameter (TRAP) [12] , lipid hydroperoxides, i.e., FOX-LOOH [13] and CL-LOOH [14] , MDA [15] , NOx [16] , SOD activity in erythrocytes [17] , CAT activity in erythrocytes [18] , SH groups [19] , total plasmatic PON1 activity [20] were assayed by previously described methods. CRP was determined by an automated immunological method (i2000SR Architect, Abbott, USA). The inter-assay CV values for all analytes were <10%.
Statistical analysis
Differences in socio-demographic, clinical and biomarker data between PD cases and normal controls were checked with ANOVAs or ANCOVAs. Tukey tests were used to examine multiple comparisons between the three study groups (controls and 2 PD subgroups). We employed 2 test (analyses of contingency tables) to examine the associations between socio-demographic and clinical data and diagnostic groups. Relationships between variables were assessed using Pearson's product moment and Spearman's rank order correlation coefficients. Univariate general linear model (GLM) analyses were used to examine the effects of diagnostic groups on the biomarkers while adjusting for background variables, such as gender, age and BMI. Multivariate GLM analysis was used to examine the effects of drugs on the biomarkers. Tests for homogeneity of variance have been carried out where appropriate (Levene test). Generalized LM (GeLM) analysis was used to examine the effects of biomarkers and socio-demographic data on the severity index. We used bivariate logistic regression analyses to delineate the significant biomarkers with Odds ratio and 95% confidence intervals of PD versus controls. The Hosmer-Lemeshow test was used to test whether the model fitted the data. All tests were 2-tailed and a p-value of 0.05 was used for statistical significance. Table 1 shows the socio-demographic, clinical and biomarker data. We did not use a Bonferroni p-correction to interpret the multiple statistical analyses on the socio-demographic and clinical data because the results of these univariate tests were employed to delineate the explanatory variables that were subsequently used in logistic regression analyses as determinants of independent association with the diagnostic groups. There were no significant differences in age, BMI, sex ratio, tobacco use (TU, that is current tobacco use + previous use versus never smoking) and ethnicity between cases and controls. Without p-correction there were significant associations between PD and marital status (more married individuals), physical activity (lower in PD), and alcohol use (lower in PD).
Results
Without p-correction, we found significant associations between age and SH groups (r = −0.391, p < 0.001, n = 110). There were significant correlations between BMI and CRP (r = 0.255, p = 0.009, n = 105), TRAP (r = 0.307, p = 0.001, n = 110) and CL-LOOH (r = −0.214, p = 0.025, n = 110). There were sex differences in SH groups (F = 12.3, df = 1/108, p < 0.001), LOOH (F = 4.22, df = 1/108, p = 0.042) and CAT activity (F = 5.62, df = 1/107, p = 0.020). Subjects with TU had significantly higher SOD activity values (F = 4.68, df = 1/107, p = 0.033). There were no significant associations between the biomarkers and alcohol abuse. Consequently, we have used sex, age, BMI and TU as additional explanatory variables in GLM analyses when examining the associations between PD and the biomarkers.
GLM analyses with diagnostic groups, sex and TU as factors and age and BMI as covariates showed significantly higher CL-LOOH, FOX-LOOH, MDA, SOD activity and CRP and lower CAT activity in PD as compared to controls. Diagnostic groups explained a large part of the variance in the biological markers, e.g., 46.5% of the variance in MDA and 19.0% of the variance in FOX-LOOH. Controlling for marital status, physical activity and alcohol use did not change any of these results. Table 2 shows that SOD activity and MDA were significantly and positively associated with PD, whereas TRAP, SH-groups and CAT activity were inversely associated with PD (results of automatic stepwise binary logistic regression analysis; X 2 = 99.51, df = 5, p < 0.001, Nagelkerke = 0.803). Using this regression equation 90.7% of all cases were correctly classified with a sensitivity of 94.5% and a specificity of 86.8%. The Hosmer-Lemeshow test showed that this model fitted the data quite well (X 2 = 4.51, df = 8, p = 0.808). Table 3 shows the characteristics of controls versus two patients groups divided according to early PD stage versus late PD stage. There were no significant differences in age, sex ratio, TU or BMI between the three study samples. GLM analyses showed that there were significant differences in FOX-LOOH, CL-LOOH, MDA, CAT activity and SOD activity between the subgroups. FOX-LOOH, CL-LOOH and SOD activity were significantly higher in late PD stage than in controls. MDA was significantly higher in both PD groups as compared to controls. CAT activity was significantly lower in late PD stage, whereas there was a trend toward significantly lower values in early PD stage (p = 0.079). Table 4 shows the outcome of a GeLM analysis with a severity score based on PD progression (i.e., 0 = controls; 1 = PD stage 1; 2 = PD stage 2; and 3 = PD stage 3) as dependent variable and the IO&NS biomarkers as explanatory variables. 58.1% of the variance (F = 28.27, df = 5/102, p < 0.001) was explained by FOX-LOOH, MDA and SOD activity (positively associated) and SH groups and CAT activity (inversely associated) with this staging score.
In order to examine the effects of the drug state on the IO&NS biomarkers, we have performed multivariate GLM analyses with the IO&NS biomarkers as dependent variables, and the diagnostic classification, sex and the drug state as fixed factors and age and BMI as covariates. Diagnostic classification remained a significant explanatory variable after adjusting for the drug state. There were no significant (at the p = 0.007 Bonferroni corrected level) effects of amantadine (F = 1.37, df = 11/86, p = 0.201), pramipexole (F = 2.2, df = 11/86, p = 0.020), biperiden (F = 1.17, df = 11/86, p = 0.320), entacapone (F = 0.46, df = 11/86, p = 0.921), levodopa + benserazide (F = 2.41, df = 11/87, p = 0.012) and antidepressants (F = 0.77, df = 11/86, p = 0.665). There was a significant effect of levodopa + carbidopa (F = 2.63, df = 11/87, p = 0.006). Tests of between-subject effects showed that levodopa + carbidopa had a significant stimulatory effect on CRP (adjusted mean ± SE, no drugs = 2.15 ± 0.54 mg/L versus drugs 9.65 ± 1.60 mg/L; F = 19.21, df = 1/97, p < 0.001). Adjusting for the use of levodopa + carbidopa in univariate GLM analysis showed that CRP was no longer significantly increased in PD patients (F = 0.40, df = 1/98, p = 0.529).
Discussion
The first major finding of this study is that PD is positively associated with increased levels of oxidative biomarkers (LOOH and MDA) and SOD activity, and inversely with antioxidant defenses, such as TRAP, SH and CAT activity, and that a combination of different biomarkers significantly predicts PD with a sensitivity of 94.5% and a specificity of 86.8%. Thus, MDA and SOD activity increase risk toward PD, whereas TRAP, SH-groups and CAT activity displayed protective effects. The single best biomarker for PD was MDA showing that an amazing 46.5% of the variance in MDA levels was associated PD.
Our findings that LOOH and MDA, which are both indicators of lipid peroxidation, are elevated in the blood of PD patients are in agreement with those of other studies [3, 21] . Sharma et al. [5] , suggest three possible mechanistic explanations for the elevated lipid peroxidation in PD: (a) lower levels of antioxidants; (b) more substrates for oxidation; and (c) the presence of yet unidentified plasma pro-oxidants in patients with PD.
In our study no significant changes in NOx levels was detected in PD. In the CNS, however, PD is not only accompanied by lipid peroxidation, but also by an increased NO metabolism [22] . High levels of NO can nitrosylate proteins thereby modifying the activity of many proteins related to intracellular signaling and immune responses. This explains that NO generated by inducible nitric oxide synthase (iNOS) may cause inflammatory responses and apoptosis. In PD, the injury to dopaminergic neurons promotes microglial activation, upregulation of iNOS and increased NO production [23] .
In this study we found that antioxidant biomarkers were inversely (TRAP, CAT and SH-groups) or positively (SOD activity) associated with PD. The decreased TRAP indicates reduced levels of hydrosoluble plasmatic antioxidants, including uric acid, glutathione, bilirubin and ascorbic acid [24] . Decreased levels of plasma antioxidants associated with markers of oxidative stress in PD patients have also been reported [5, 24] . Moreover, our results that SH is lowered in PD patients are in agreement with those of [5] . Although we could not find lowered PON1 activity in our patients previous research reported reduced plasma PON-1 activity in PD patients [7] .
Our CAT and SOD activity findings are in agreement with the results of previous studies [3, 5] . Increased SOD activity may constitute a compensatory mechanism to counteract increased production of superoxide radicals. The increase in SOD activity improves the scavenging of O 2 −• , however generates H 2 O 2 , which in the presence of iron may become an additional source of ROS. In this way, decreased CAT activity may reflect increased consumption in order to decompose H 2 O 2 . Sharma et al. [5] found that increased SOD activity may be ascribed to the effects of various ROS, which are produced during chronic oxidative stress in these patients. However, there are also some contradictory results in PD showing decreased SOD activity in the peripheral blood [25, 26] .
Another major finding of this study is that some biomarkers are associated with early or late staging of illness. LOOH and SOD activity are significantly increased in late PD stage, but not in early PD stage, while MDA is increased in early and late PD stages. These findings suggest that with progression of illness (from early stage to late stage) there is a gradual increase in LOOH and SOD activity. Thus, while MDA is a highly significant biomarker of PD per se, changes in LOOH and SOD activity are more associated with disease progression. Our results may suggest that lipid peroxidation with the formation of neoepitopes like MDA is a key phenomenon of PD that further drives adaptive changes in SOD and CAT activity.
The results of the present study show that pathophysiological features of PD are detectable in the peripheral blood and that increased LOOH and SOD activity, but not MDA, are additionally biomarkers of disease progression. Lowered levels of TRAP, SH-groups and CAT activity may increase susceptibility to inflammation and damage by O&NS and lipid peroxidation [23] . Previously, we have discussed the pathways that translate peripheral IO&NS signals to central neuro-inflammatory responses, including vagus nerve signaling and blood-brain-barrier permeability pathways. Microglia-associated neuro-inflammation with increased levels of pro-inflammatory mediators and ROS may play a role in the neuronal degeneration in PD [27] . Peripheral and central IO&NS processes occur in the prodromal stage of the disease and may sustain disease progression [28] . Therefore it may be concluded that the interplay between peripheral and central IO&NS processes is a key component in the pathophysiology of PD which is associated with the onset as well as progression of PD.
In this study, we found that the antiparkinson drugs used did not affect the O&NS biomarkers, which support in vitro and clinical studies showing that levodopa treatment does not increase oxidative damage [29, 30] . Adjusting our results for the effects of levodopa + carbidopa showed that the increased CRP levels in PD were no longer significant and that patients who were taking levodopa + carbidopa had significantly higher CRP levels. Previously, increased CRP levels in 17 individuals taking carbidopa + levodopa was reported to the USFDA (http://www.ehealthme.com/print/ ds18298141). Although increased CRP in PD may be an artifact of the drug state of the patients, there are reports showing increased levels of pro-inflammatory cytokines, including IL-6 (which mediates CRP plasma levels) in the plasma and brain of PD patients [11] . All in all, the antiparkinson drugs used in our study did not attenuate the systemic O&NS processes, while levodopa + carbidopa even increased the inflammatory state. Since O&NS processes appear to be important in the pathophysiology of PD it may be suggested that treatments using the current antiparkinson drugs should be combined with drugs targeting lipid peroxidation and lowered antioxidant levels.
This study has some limitations and strengths that must be considered when interpreting the data. The limitations are: (1) as this is a cross-sectional case-control study, we cannot draw firm conclusions on causality; (2) the smaller number of participants in the PD and control groups; and (3) indicants of neuro-inflammation were not measured. Strengths are that all our results are controlled for possible effects of intervening variables, including gender, age, BMI, tobacco and alcohol use, the drug state of the patients, other medical illnesses and use of antioxidant supplements.
In conclusion, plasma MDA may serve as a highly sensitive and specific disease biomarker, while plasma LOOH and SOD activity may serve as staging biomarkers of PD. These pathophysiological hallmarks of PD can be measured in the peripheral blood. New treatments for PD should not only target dopaminergic pathways but also lipid peroxidation and lowered antioxidant defenses.
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